Lorena Passoni

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint ALK a novel lymphoma-associated tumor antigen for vaccination strategies
    Lorena Passoni
    Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Leuk Lymphoma 44:1675-81. 2003
  2. ncbi request reprint In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas
    Lorena Passoni
    Oncogenic Fusion Protein Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Haematologica 91:48-55. 2006
  3. doi request reprint Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients
    Lorena Passoni
    Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Cancer Res 69:7338-46. 2009
  4. ncbi request reprint ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes
    Lorena Passoni
    Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Blood 99:2100-6. 2002
  5. ncbi request reprint Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo
    Addolorata Maria Luce Coluccia
    Department of Experimental Oncology, National Cancer Institute, Milan, Italy
    Blood 103:2787-94. 2004

Detail Information

Publications5

  1. ncbi request reprint ALK a novel lymphoma-associated tumor antigen for vaccination strategies
    Lorena Passoni
    Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Leuk Lymphoma 44:1675-81. 2003
    ....
  2. ncbi request reprint In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas
    Lorena Passoni
    Oncogenic Fusion Protein Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Haematologica 91:48-55. 2006
    ..One of the promising ALK-targeted therapeutic options is cancer vaccination. In this study, we investigate whether ALK is a tumor-associated antigen suitable for immune interventions...
  3. doi request reprint Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients
    Lorena Passoni
    Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Cancer Res 69:7338-46. 2009
    ..Alternative mechanisms other than direct mutations and/or gene amplification regulate the ALK level of expression in NBL cells. Wild-type ALK is a potential therapeutic target for advanced/metastatic NBLs...
  4. ncbi request reprint ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes
    Lorena Passoni
    Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Blood 99:2100-6. 2002
    ....
  5. ncbi request reprint Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo
    Addolorata Maria Luce Coluccia
    Department of Experimental Oncology, National Cancer Institute, Milan, Italy
    Blood 103:2787-94. 2004
    ..Bcl-XL deserves further investigation as a possible therapeutic target in ALK+ ALCLs...